Related Experiment Video
Updated: May 31, 2026
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)
Published on: March 7, 2017
Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology
M H A Jansen1, D G van Vuurden, W P Vandertop
1Department of Pediatrics, Division of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands. mh.jansen@vumc.nl
Abstract:
Patients with diffuse intrinsic pontine gliomas (DIPG) have a poor prognosis. Although DIPG constitute only 10-15% of all pediatric brain tumors, they are the main cause of death in this group. Despite 26 clinical trials in newly diagnosed DIPG in the past 5years (including several targeted agents), there is no clear improvement in prognosis. However, knowledge on DIPG biology is increasing, mainly due to the (re)introduction of biopsies and autopsies, the possibility of gene expression profiling, and the development of in vivo models. Translation of this knowledge into clinical trials in combination with improved drug distribution methods may eventually lead to more effective treatment of this devastating disease.
Insights
Diffuse intrinsic pontine gliomas (DIPG) remain a deadly pediatric brain tumor with poor prognosis. Advances in understanding DIPG biology offer hope for developing more effective treatments through targeted therapies and improved drug delivery.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Cancer Biology
Background:
- Diffuse intrinsic pontine gliomas (DIPG) are aggressive pediatric brain tumors with a dismal prognosis.
- DIPG are the leading cause of cancer-related death in children, despite accounting for a small percentage of pediatric brain tumors.
- Recent clinical trials for newly diagnosed DIPG have not yielded significant improvements in patient outcomes.
Purpose of the Study:
- To review the current understanding of DIPG biology.
- To explore the potential of translating new biological insights into improved clinical treatments.
- To highlight the importance of enhanced drug delivery strategies for DIPG therapy.
Main Methods:
- Review of recent scientific literature on DIPG.
- Analysis of outcomes from recent clinical trials in DIPG.
- Discussion of advancements in DIPG research, including biopsies, gene expression profiling, and in vivo models.
Main Results:
- Despite numerous clinical trials, there has been no substantial improvement in DIPG prognosis.
- Increasing knowledge of DIPG biology is emerging from new research methodologies.
- Improved drug distribution methods are crucial for enhancing treatment efficacy.
Conclusions:
- Further research into DIPG biology is essential for therapeutic development.
- Integrating biological knowledge with improved drug delivery in clinical trials may offer future treatment advancements.
- Addressing the poor prognosis of DIPG requires a multi-faceted approach combining biological understanding and innovative therapeutic strategies.
